Cereno Scientific Announces Program and Speakers for the Capital Markets Day on February 5, 2026

Cereno Scientific will host a Capital Markets Day on February 5, 2026 (Stockholm and virtual) to present updates on its clinical development, strategic priorities and growth ambitions. Management and external experts will highlight plans to advance lead HDAC inhibitor CS1 into a Phase IIb program following encouraging Phase IIa signals and an Expanded Access Program, review other pipeline assets (CS014, CS585) and outline the company’s strategic focus; the company trades on Nasdaq First North (CRNO B).

Analysis

Market structure: A credible Phase IIb push for CS1 (HDAC inhibitor for PAH) primarily benefits small-cap rare-disease biotech investors and specialty CROs; suppliers of trial services and the clinical-stage partner ecosystem could see increased demand over 6–12 months. Established PAH commercial incumbents (e.g., United Therapeutics, UTHR) face limited immediate pricing pressure because CS1 is disease-modifying and early-stage—market-share impact is multi-year and contingent on positive Phase IIb readouts. Balance of supply/demand is idiosyncratic: more investor capital and trial sites chase a narrower set of PAH assets, raising equity financing probability and potential dilution risk within 12 months. Cross-asset: move is equity-specific but will modestly widen credit spreads for small biotech borrowers and lift biotech sector IV around the Feb 5 CMD; FX/commodities negligible.

Key Decisions for Investors

• Establish a tactical long in Cereno Scientific (CRNO B) sized 2–3% of NAV ahead of the Feb 5, 2026 Capital Markets Day to capture potential re-rate; target a +40% move within 3 months on clear Phase IIb timing/strategy, and apply a hard stop at -30% to limit binary trial risk.
• If options are available, allocate 0.5–1.0% of NAV to a short-dated (Feb–Mar 2026) straddle or buy ATM straddle to capture a binary CMD move; if IV is already >60%, prefer a 6–12 month call (size 1% NAV, strike ~+50%) to retain asymmetry for Phase IIb upside.
• Run a relative-value pair: long CRNO B (2% NAV) / short United Therapeutics (UTHR) (1% NAV) to express idiosyncratic PAH upside while hedging sector risk; unwind within 6–12 months or on Phase IIb start announcement.
• Trim 1–2% exposure to large-cap PAH/rare-disease commercial names (e.g., UTHR) and redeploy into selective small-cap rare-disease innovators where binary clinical upside >30%; require confirmation of CS1 Phase IIb start within 90 days or reduce CRNO B position by 50% to avoid dilution risk.